More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
New benefits for certain COVID-19 patients, including reduced need for respiratory intervention, have been found for Merck’s COVID-19 pill molnupiravir.
Poor sleep linked to more COPD flare-ups: NIH study
By
Alicia Lasek (f3)
Jun 07, 2022
Poor sleep quality is a good predictor of whether a patient with COPD will have exacerbations, researchers say.
Clinical briefs for Tuesday, June 7
By
Alicia Lasek (f3)
Jun 07, 2022
NIC: Residents’ care needs have grown as staffing remains top challenge for operators … FDA: Novavax’s COVID-19 vaccine effective, but heart risks a concern … U.S. cancer screenings fell 80% during...
Discard portable bed rails linked to long-term care deaths, CPSC warns
By
Alicia Lasek (f3)
Jun 06, 2022
The Consumer Products Safety Commission is warning against the use of Mobility Transfer Systems adult portable bed rails, which are tied to the deaths of three people.
Common autoimmune drugs reduce mortality, up clinical status in COVID-19: NIH
By
Alicia Lasek (f3)
Jun 06, 2022
Two commonly used autoimmune drugs could be used in addition to standard-of-care treatments to improve COVID-19 outcomes, the agency says.
New study links sarcopenic obesity to dementia; experts call for preventive action
By
Alicia Lasek (f3)
May 26, 2022
Obesity with decreased muscle mass and function is prevalent in older adults and is tied to a high risk of dementia, researchers say.
Clinical briefs for Tuesday, May 3
By
Alicia Lasek (f3)
May 03, 2022
Paxlovid does not prevent COVID-19, new trial data show … Black and white patients have had similar risk of MS for decades, study finds … Parkinson’s drug hopeful found safe in early clinical trial...
‘A long time coming’: LTC infection preventionists get new certification option
By
Alicia Lasek (f3)
Apr 27, 2022
A new opportunity to receive industry-specific IPC board certification is a much-needed chance for LTC workers to build and show their niche expertise, experts say.
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
Clinical briefs for Friday, April 22
By
Alicia Lasek (f3)
Apr 22, 2022
New data: AstraZeneca’s COVID-19 antibody Evusheld confers 83% protection at six months … Simple test in certain pneumonia patients could help cut broad-spectrum antibiotics use … Faster onset of...